Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NYM005 in metastatic clear cell renal carcinoma
NCT06389682Phase 2Completed
- Sponsor
- Norroy Bioscience
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-NYM005 in clear cell renal cell carcinoma (ccRCC), sponsored by Norroy Bioscience. Started Jun 2024; status: completed.
02
Drugs
68Ga-NYM005
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06389682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389682.